Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
3.83
Nov 17 • 3:51 PM ET Dollar change-0.37 Percentage change(-8.71%)
Index
RUT
Market Cap
695.85M
Enterprise Value
745.11M
Income
-176.35M
Sales
7.06M
Book/sh
0.05
Cash/sh
0.34
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
146
IPO
Oct 20, 2022
P/E
-
Forward P/E
-
PEG
-
P/S
98.56
P/B
82.24
P/C
11.38
P/FCF
-
EV/EBITDA
-
EV/Sales
105.54
Quick Ratio
1.79
Current Ratio
1.79
Debt/Eq
13.08
LT Debt/Eq
11.97
Option/Short
Yes / Yes
EPS (ttm)
-0.99
EPS next Y
-0.84
EPS next Q
-0.23
EPS this Y
29.63%
EPS next Y
11.23%
EPS next 5Y
14.79%
EPS past 3/5Y
2.55% -91.28%
Sales past 3/5Y
- -2.32%
EPS Y/Y TTM
32.90%
Sales Y/Y TTM
18.14%
EPS Q/Q
30.36%
Sales Q/Q
243.92%
Insider Own
46.28%
Insider Trans
0.00%
Inst Own
48.47%
Inst Trans
3.22%
ROA
-58.90%
ROE
-207.16%
ROIC
-161.14%
Gross Margin
-3.04%
Oper. Margin
-2584.24%
Profit Margin
-2497.56%
SMA20
-11.28%
SMA50
3.02%
SMA200
9.10%
Trades
Shs Outstand
181.39M
Shs Float
97.73M
52W High
5.91 -35.28%
52W Low
2.67 43.26%
Volatility
10.93% 11.72%
ATR (14)
0.48
RSI (14)
46.66
Beta
2.17
Rel Volume
0.84
Avg Volume
4.53M
Volume
3,746,772
Perf Week
-1.92%
Perf Month
-0.13%
Perf Quarter
8.05%
Perf Half Y
41.67%
Perf YTD
10.23%
Perf Year
0.13%
Perf 3Y
-42.05%
Perf 5Y
-
Perf 10Y
-
Prev Close
4.19
Price
3.83
Change %
-8.71%
Consensus
Strong Buy
Avg. Price Target
$7.62
Implied Upside
+99.2%
Analysts12incl. previous ratings
Rating Distribution8 Buy · 4 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Aug 25, 2026Resumed
CChardan Capital Markets
Buy$7+83.0%
Aug 19, 2026Initiated
BMO logoBBMO Capital Markets
Outperform$9+135.3%
Jun 29, 2026Upgrade
HH.C. Wainwright
Neutral → Buy$8+109.2%
Mar 12, 2026Initiated
OPY logoOOppenheimer
Outperform$11+187.6%
May 27, 2025Downgrade
C logoCCitigroup
Buy → Neutral$1.50-60.8%
May 20, 2025Downgrade
JPM logoJJP Morgan
Overweight → Neutral
May 20, 2025Downgrade
HH.C. Wainwright
Buy → Neutral
Dec 10, 2024Initiated
JJMP Securities
Mkt Outperform$10+161.4%
May 20, 2024Initiated
HH.C. Wainwright
Buy$10+161.4%
May 16, 2024Upgrade
C logoCCitigroup
Neutral → Buy$10+161.4%
Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.
M.P.A.Mr. Jeffrey D. Marrazzo M.B.A.
CEO & DirectorDr. Allan Reine M.D.
Chief Technical OfficerDr. Ann L. Lee Ph.D.
Ph.D.Dr. Andrew Anzalone M.D.
Co-Founder & Member of Scientific Advisory BoardDr. David R. Liu Ph.D.